Search COVID-19 Rapid Resource Center or explore resources sorted by Category or Content Type.
Consideration of Severe Coronavirus Disease 2019 As Viral Sepsis and Potential Use of Immune Checkpoint Inhibitors
From Critical Care Explorations.
Supportive treatment and immunomodulators have a critical place in the treatment of severe patients until effective antivirals are developed. Interleukin-6 antagonists, one of the immunomodulating agents, appears to be effective in the treatment of cytokine storm, but some patients continue to have severe lymphopenia and immunosuppression.
The authors believe it can be useful as immunomodulator therapy in critical COVID-19 patients because of the benefits of immune checkpoint inhibitors in cancer and sepsis patients.
Odabasi Z, Cinel I.
Estimated Time: 13:50 min